Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabidiol in Fragile-X Syndrome
NCT06261502Phase 2Recruiting
- Sponsor
- Université de Sherbrooke
- Start
- Sep 2025
- Primary completion
- Jul 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cannabidiol in Fragile X syndrome (FXS), sponsored by Université de Sherbrooke. Started Sep 2025; status: recruiting.
02
Drugs
cannabidiol
03
Conditions
Fragile X syndrome (FXS)
Beyond the preview
Go deeper on NCT06261502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06261502.